Wall Street Signals: Koios Launches Clinical Trials to Study Efficacy of Drinks

Koios Launches Clinical Trials to Study Efficacy of Drinks

VANCOUVER , May 22, 2018 /CNW/ - Koios Beverage Corp. (CSE: KBEV; OTC: SNOVF) (the "Company" or "Koios"), which makes brain healthy beverages that can improve cognitive function, is pleased to announce it has entered into an agreement with NeuraPerformance/Neuroptimize Brain Center whereby NeuraPerformance/Neuroptimize will perform full clinical brain scans on Koios users.
NeuraPerformance/Neuroptimize is the go-to brain lab and physiotherapy clinic for Colorado's elite athletes, including the Denver Broncos football team. The centre specializes in brain mapping, brainwave optimization, enhancing sports performance, baseline concussion testing and treatment.
NeuraPerformance/Neuroptimize will also stock and sell Koios beverages in the future, at its numerous locations.
"Our respective companies have a shared vision and passion for mental health and performance," said Rachel Ragsdale , director of brain mapping, neurofeedback and counselling at NeuraPerformance/Neuroptimize. "Helping them demonstrate the efficacy of their products is something we truly look forward to doing.  Additionally, adding their products to our platform of services creates tremendous value for our clients and the people we are trying to help.  Mixing technical science with their stellar products is a win for everyone."
The full clinical brain-scan study may provide evidence that Koios products may enhance cognition over the long term and help the Company fine-tune its beverages' performance.
"For many years we have been looking for the right partner and platform to test our technologies and products," said Chris Miller , CEO of Koios. "Not only will this clinical trial further substantiate our product formulation, but the data collected will pave the way to creating better technologies within our portfolio, and fulfiling our mission of creating some of the most functional organic products that support and enhance brain health and performance."
The initial results of the study are expected in July.

About the Company's Business
The Company, through its entirely possessed auxiliary Koios, Inc., is a developing useful refreshment organization which has an accessible dissemination system of in excess of 2,000 retail stores over the United States in which to offer its items. Koios has associations with a portion of the biggest and most trustworthy wholesalers in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well. Together these merchants speak to in excess of 80,000 blocks and mortar areas over the United States - from sports sustenance stores to vast normal basic supply chains including Whole Foods and Sunflower markets. Through its association with Wishing-U-Well, Koios likewise appreciates a substantial nearness web-based, including being an Amazon decision item. 
Koios utilizes a restrictive mix of nootropics and normal natural mixes to improve human profitability without utilizing destructive chemicals or stimulants. Koios items can upgrade center, fixation, mental limit, memory maintenance, subjective capacity, sharpness, mind limit and make throughout the day mental lucidity. Its fixings are particularly intended to target mind work by expanding bloodstream, oxygen levels and neural associations in the cerebrum.
Koios is one of the only drinks in the world to infuse its products with MCT oil.  MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/
On behalf of the Board of Directors of the Company.
KOIOS BEVERAGE CORP.
"Chris Miller"
Chris Miller , CEO and Director
Forward-Looking Statements
This news discharge contains forward-looking explanations. All announcements, other than explanations of authentic actuality that address exercises, occasions or improvements that the Company trusts, expects or suspects will or may happen later on are forward-looking proclamations. Forward-looking explanations in this news discharge incorporate articulations as for the announcement that the clinical outputs will yield logical confirmation with respect to the adequacy of the Company's items and empower the Company to enhance its items; and the announcement that the underlying aftereffects of the clinical sweeps are normal in July. The forward-looking proclamations mirror administration's present desires in view of data right now accessible and are liable to various dangers and vulnerabilities that may make results contrast physically from those examined in the forward-looking explanations including: (I) unfavorable economic situations; (ii) the powerlessness of the Company and NeuraPerformance/Neuroptimize to finish the clinical outputs on time or by any stretch of the imagination; and (iii) that the clinical sweeps, if finished, may not yield logical confirmation of the adequacy of the Company's items. In spite of the fact that the Company trusts that the desires reflected in the forward-looking articulations are sensible, it can't ensure future outcomes, levels of movement or execution. Further, any forward-looking articulation talks just as of the date on which such proclamation is made and, with the exception of as required by material law, the Company embraces no commitment to refresh any forward-looking explanation to reflect occasions or conditions after the date on which such proclamation is made or to mirror the event of unexpected occasions. New factors rise up out of time to time, and it isn't workable for administration to anticipate all of such factors and to survey ahead of time the effect of such factors on the Company's business or the degree to which any factor, or mix of components, may make real outcomes vary tangibly from those contained in any forward-looking proclamation. Perusers ought to counsel the majority of the data put forward in this and ought to likewise allude to the hazard factor exposure laid out in the Company's records documented now and again with the British Columbia Securities Commission on SEDAR at www.sedar.com.